Table 2.
Use of medications, according the study period.
| Medication | Pre-guideline period (n = 662) |
Post-guideline
period (n = 703) |
p-value |
|---|---|---|---|
|
Bronchodilators |
|||
| Nebulized beta 2 agonists | 302 (45.6%) | 24 (3.4%) | <0.001 |
| Inhaled beta 2 agonists | 465 (70.2%) | 483 (68.7%) | 0.421 |
| Nebulized anticholinergics | 22 (3.3%) | 10 (1.4%) | 0.029 |
| Inhaled anticholinergics | 10 (1.5%) | 11 (1.6%) | 1.00 |
| Nebulized epinephrine | 107 (16.2%) | 55 (7.8%) | <0.001 |
| Anti-inflammatories | |||
| Inhaled corticosteroids | 16 (2.4%) | 17 (2.4%) | 1.00 |
| Systemic corticosteroids | 43 (6.5%) | 37 (5.3%) | 0.389 |
| Nebulized hypertonic saline | 527 (79.6%) | 645 (91.7) | <0.001 |
| Antibiotics | 71 (10.7%) | 64 (9.1%) | 0.444 |